Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.68 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.54 |
| ▸ | TNKS | O95271 | 3/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.50 |
| ▸ | WNT3A | P56704 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23575033 | 0.86 | TNKS (0.50) | COMTTNKSTNKS2PARP1 | |
| SCHEMBL4770414 | 0.82 | NPY5R (0.49) | — | |
| SCHEMBL11422025 | 0.82 | PIN1 (0.62) | COMTSCN2AKDM4E | |
| SCHEMBL4376727 | 0.81 | KDM4E (0.76) | COMTKDM4EL3MBTL1 | |
| SCHEMBL2433653 | 0.81 | COMT (1.00) | COMTSCN2ATNKSTNKS2WNT3A | |
| SCHEMBL3536070 | 0.81 | SCN2A (0.50) | SCN2ATNKSTNKS2 | |
| SCHEMBL8948970 | 0.78 | KDM6B (0.44) | — | |
| SCHEMBL31422809 | 0.75 | COMT (0.54) | COMTSCN2ATNKSTNKS2WNT3A | |
| SCHEMBL5833712 | 0.75 | COMT (0.65) | COMTSCN2ATNKSTNKS2WNT3A | |
| SCHEMBL9205892 | 0.75 | GUSB (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | HICKEY DEIDRE MARY BERNADETTE | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | PLA2G4A, PLA2G4B, PLA2G1B | COMT 1709/4885SCN2A 4000/4885TNKS 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.